181 related articles for article (PubMed ID: 31904851)
1. MRP8/14 and neutrophil elastase for predicting treatment response and occurrence of flare in patients with juvenile idiopathic arthritis.
Barendregt AM; Veldkamp SR; Hissink Muller PCE; van de Geer A; Aarts C; van Gulik EC; Schilham MW; Kessel C; Keizer MP; Hemke R; Nassar-Sheikh Rashid A; Dolman KM; Schonenberg-Meinema D; Ten Cate R; van den Berg JM; Maas M; Kuijpers TW
Rheumatology (Oxford); 2020 Sep; 59(9):2392-2401. PubMed ID: 31904851
[TBL] [Abstract][Full Text] [Related]
2. MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis.
Anink J; Van Suijlekom-Smit LW; Otten MH; Prince FH; van Rossum MA; Dolman KM; Hoppenreijs EP; ten Cate R; Ursu S; Wedderburn LR; Horneff G; Frosch M; Vogl T; Gohar F; Foell D; Roth J; Holzinger D
Arthritis Res Ther; 2015 Aug; 17(1):200. PubMed ID: 26249667
[TBL] [Abstract][Full Text] [Related]
3. Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy.
Hinze CH; Foell D; Johnson AL; Spalding SJ; Gottlieb BS; Morris PW; Kimura Y; Onel K; Li SC; Grom AA; Taylor J; Brunner HI; Huggins JL; Nocton JJ; Haines KA; Edelheit BS; Shishov M; Jung LK; Williams CB; Tesher MS; Costanzo DM; Zemel LS; Dare JA; Passo MH; Ede KC; Olson JC; Cassidy EA; Griffin TA; Wagner-Weiner L; Weiss JE; Vogler LB; Rouster-Stevens KA; Beukelman T; Cron RQ; Kietz D; Schikler K; Mehta J; Ting TV; Verbsky JW; Eberhard AB; Huang B; Giannini EH; Lovell DJ
Arthritis Rheumatol; 2019 Mar; 71(3):451-459. PubMed ID: 30225949
[TBL] [Abstract][Full Text] [Related]
4. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial.
Foell D; Wulffraat N; Wedderburn LR; Wittkowski H; Frosch M; Gerss J; Stanevicha V; Mihaylova D; Ferriani V; Tsakalidou FK; Foeldvari I; Cuttica R; Gonzalez B; Ravelli A; Khubchandani R; Oliveira S; Armbrust W; Garay S; Vojinovic J; Norambuena X; Gamir ML; García-Consuegra J; Lepore L; Susic G; Corona F; Dolezalova P; Pistorio A; Martini A; Ruperto N; Roth J;
JAMA; 2010 Apr; 303(13):1266-73. PubMed ID: 20371785
[TBL] [Abstract][Full Text] [Related]
5. The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis.
Holzinger D; Frosch M; Kastrup A; Prince FH; Otten MH; Van Suijlekom-Smit LW; ten Cate R; Hoppenreijs EP; Hansmann S; Moncrieffe H; Ursu S; Wedderburn LR; Roth J; Foell D; Wittkowski H
Ann Rheum Dis; 2012 Jun; 71(6):974-80. PubMed ID: 22267331
[TBL] [Abstract][Full Text] [Related]
6. Use of MRP8/14 in clinical practice as a predictor of outcome after methotrexate withdrawal in patients with juvenile idiopathic arthritis.
Sumner EJ; Almeida B; Palman J; Bale P; Heard C; Holzinger D; Roth J; Foell D; Robinson E; Ursu S; Wallace C; Gilmour K; Wedderburn LR; Ralph E
Clin Rheumatol; 2022 Sep; 41(9):2825-2830. PubMed ID: 35486225
[TBL] [Abstract][Full Text] [Related]
7. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis.
Choi IY; Gerlag DM; Herenius MJ; Thurlings RM; Wijbrandts CA; Foell D; Vogl T; Roth J; Tak PP; Holzinger D
Ann Rheum Dis; 2015 Mar; 74(3):499-505. PubMed ID: 24297376
[TBL] [Abstract][Full Text] [Related]
8. Myeloid-related protein 8/14 in plasma and serum in patients with new-onset juvenile idiopathic arthritis in real-world setting in a single center.
Keskitalo PL; Kangas SM; Sard S; Pokka T; Glumoff V; Kulmala P; Vähäsalo P
Pediatr Rheumatol Online J; 2022 Jun; 20(1):42. PubMed ID: 35710418
[TBL] [Abstract][Full Text] [Related]
9. Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study.
Gerss J; Roth J; Holzinger D; Ruperto N; Wittkowski H; Frosch M; Wulffraat N; Wedderburn L; Stanevicha V; Mihaylova D; Harjacek M; Len C; Toppino C; Masi M; Minden K; Saurenmann T; Uziel Y; Vesely R; Apaz MT; Kuester RM; Elorduy MJ; Burgos-Vargas R; Ioseliani M; Magni-Manzoni S; Unsal E; Anton J; Balogh Z; Hagelberg S; Mazur-Zielinska H; Tauber T; Martini A; Foell D;
Ann Rheum Dis; 2012 Dec; 71(12):1991-7. PubMed ID: 22689317
[TBL] [Abstract][Full Text] [Related]
10. Myeloid related proteins MRP8/MRP14 may predict disease flares in juvenile idiopathic arthritis.
Schulze zur Wiesch A; Foell D; Frosch M; Vogl T; Sorg C; Roth J
Clin Exp Rheumatol; 2004; 22(3):368-73. PubMed ID: 15144135
[TBL] [Abstract][Full Text] [Related]
11. Myeloid-related Protein 8/14 Levels in Rheumatoid Arthritis: Marker of Disease Activity and Response to Methotrexate.
Patro PS; Singh A; Misra R; Aggarwal A
J Rheumatol; 2016 Apr; 43(4):731-7. PubMed ID: 26834220
[TBL] [Abstract][Full Text] [Related]
12. Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs.
de Moel EC; Rech J; Mahler M; Roth J; Vogl T; Schouffoer A; Goekoop RJ; Huizinga TWJ; Allaart CF; Toes REM; Schett G; van der Woude D
Arthritis Res Ther; 2019 Dec; 21(1):268. PubMed ID: 31805992
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop?
Foell D; Frosch M; Schulze zur Wiesch A; Vogl T; Sorg C; Roth J
Ann Rheum Dis; 2004 Feb; 63(2):206-8. PubMed ID: 14722212
[TBL] [Abstract][Full Text] [Related]
14. Myeloid related protein 8 and 14 secretion reflects phagocyte activation and correlates with disease activity in juvenile idiopathic arthritis treated with autologous stem cell transplantation.
Wulffraat NM; Haas PJ; Frosch M; De Kleer IM; Vogl T; Brinkman DM; Quartier P; Roth J; Kuis W
Ann Rheum Dis; 2003 Mar; 62(3):236-41. PubMed ID: 12594109
[TBL] [Abstract][Full Text] [Related]
15. A Personalized Approach to Biological Therapy Using Prediction of Clinical Response Based on MRP8/14 Serum Complex Levels in Rheumatoid Arthritis Patients.
Nair SC; Welsing PM; Choi IY; Roth J; Holzinger D; Bijlsma JW; van Laar JM; Gerlag DM; Lafeber FP; Tak PP
PLoS One; 2016; 11(3):e0152362. PubMed ID: 27029006
[TBL] [Abstract][Full Text] [Related]
16. Validation of relapse risk biomarkers for routine use in patients with juvenile idiopathic arthritis.
Rothmund F; Gerss J; Ruperto N; Däbritz J; Wittkowski H; Frosch M; Wulffraat NM; Wedderburn LR; Holzinger D; Gohar F; Vastert SJ; Brik R; Deslandre CJ; Melo-Gomes JA; Saad Magalhaes C; Barcellona R; Russo R; Gattorno M; Martini A; Roth J; Foell D;
Arthritis Care Res (Hoboken); 2014 Jun; 66(6):949-55. PubMed ID: 24339418
[TBL] [Abstract][Full Text] [Related]
17. Clinical Significance of Myeloid-Related Protein 8/14 as a Predictor for Biological Treatment and Disease Activity in Rheumatoid Arthritis.
Yunchun L; Yue W; Jun FZ; Qizhu S; Liumei D
Ann Clin Lab Sci; 2018 Jan; 48(1):63-68. PubMed ID: 29530998
[TBL] [Abstract][Full Text] [Related]
18. MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes.
Wittkowski H; Kuemmerle-Deschner JB; Austermann J; Holzinger D; Goldbach-Mansky R; Gramlich K; Lohse P; Jung T; Roth J; Benseler SM; Foell D
Ann Rheum Dis; 2011 Dec; 70(12):2075-2081. PubMed ID: 21908452
[TBL] [Abstract][Full Text] [Related]
19. The Role of Serum Calprotectin in Defining Disease Outcomes in Non-Systemic Juvenile Idiopathic Arthritis: A Pilot Study.
d'Angelo DM; Attanasi M; Di Donato G; Lapergola G; Flacco M; Chiarelli F; Altobelli E; Breda L
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675189
[TBL] [Abstract][Full Text] [Related]
20. Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial.
Hissink Muller P; Brinkman DMC; Schonenberg-Meinema D; van den Bosch WB; Koopman-Keemink Y; Brederije ICJ; Bekkering PW; Kuijpers TW; Van Rossum M; van Suijlekom-Smit LWA; van den Berg JM; Boehringer S; Allaart CF; Ten Cate R
Ann Rheum Dis; 2019 Jan; 78(1):51-59. PubMed ID: 30309970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
